NCT07221500 2026-03-16
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Nurix Therapeutics, Inc.
Phase 2 Recruiting
Clinical Trials
108 trialsNCT07015242 2026-03-11
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2 Recruiting
NCT05479994 2026-03-04
Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
BeOne Medicines
Phase 2 Active not recruiting
NCT05714345 2026-03-02
EXPAND
Allogene Therapeutics
Phase 2 Terminated
NCT04570423 2026-02-18
A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy
Spectrum Pharmaceuticals, Inc
Phase 2 Recruiting
NCT04977024 2026-02-11
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
GeoVax, Inc.
Phase 2 Active not recruiting
NCT02337829 2026-01-08
Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL
Acerta Pharma BV
Phase 2 Completed
NCT06425302 2026-01-08
GOLSEEK-2
Celgene
Phase 2 Active not recruiting
NCT05952037 2026-01-02
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia
BeOne Medicines
Phase 2 Active not recruiting
NCT07244380 2025-11-24
Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL.
Hebei Senlang Biotechnology Inc., Ltd.
Phase 2 Not yet recruiting
NCT05951959 2025-10-21
TrAVeRse
AstraZeneca
Phase 2 Active not recruiting
NCT02998476 2025-08-22
A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)
Incyte Corporation
Phase 2 Completed
NCT05673785 2025-07-14
A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)
Takeda
Phase 2 Active not recruiting
NCT03144674 2025-07-11
A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)
Incyte Corporation
Phase 2 Completed
NCT05972720 2025-05-15
FIRCE-1
CARGO Therapeutics
Phase 2 Terminated
NCT04792489 2025-04-24
DALY II USA/ MB-CART2019.1 for DLBCL
Miltenyi Biomedicine GmbH
Phase 2 Recruiting
NCT06915246 2025-04-10
A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
VIVUS LLC
Phase 2 Recruiting
NCT03235544 2025-03-18
(CITADEL-205)
Incyte Corporation
Phase 2 Completed
NCT03126019 2025-03-14
CITADEL-203
Incyte Corporation
Phase 2 Completed
NCT02924272 2025-03-12
Ixazomib Rollover Study
Takeda
Phase 2 Completed
NCT03744676 2025-02-27
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)
Juno Therapeutics, a Subsidiary of Celgene
Phase 2 Completed
NCT05144009 2025-01-30
LOTIS-9
ADC Therapeutics S.A.
Phase 2 Terminated
NCT04305444 2025-01-08
Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas
Zhejiang DTRM Biopharma
Phase 2 Terminated
NCT03484702 2024-12-27
TRANSCENDWORLD
Celgene
Phase 2 Completed
NCT04434937 2024-10-23
Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)
Incyte Corporation
Phase 2 Completed
NCT05406401 2024-10-15
waveLINE-007
Merck Sharp & Dohme LLC
Phase 2 Active not recruiting
NCT02464228 2024-06-26
PTCL
Kura Oncology, Inc.
Phase 2 Completed
NCT00268853 2024-05-30
RAPID
CTI BioPharma
Phase 2 Completed
NCT05493800 2024-05-29
Capella
MitoImmune Therapeutics
Phase 2 Active not recruiting
NCT04052997 2024-03-28
Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma
ADC Therapeutics S.A.
Phase 2 Completed
NCT04699461 2023-10-23
LOTIS-6
ADC Therapeutics S.A.
Phase 2 Terminated
NCT02226965 2023-06-29
PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine)
Sierra Oncology LLC - a GSK company
Phase 2 Completed
NCT02378038 2023-06-29
PNT2258 for Treatment of Patients With Richter's Transformation (Brighton)
Sierra Oncology LLC - a GSK company
Phase 2 Terminated
NCT01733238 2023-06-22
Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
Sierra Oncology LLC - a GSK company
Phase 2 Completed
NCT00071071 2023-05-18
Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin.
Genmab
Phase 2 Completed
NCT00071084 2023-04-28
Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin.
Genmab
Phase 2 Completed
NCT03370185 2023-02-28
BRIO
SecuraBio
Phase 2 Withdrawn
NCT05007652 2023-02-21
A Study of KRN125 in Patients With Multiple Myeloma and Malignant Lymphoma
Kyowa Kirin Co., Ltd.
Phase 2 Completed
NCT05446688 2022-07-07
A Clinical Study of 6MW3211 Injection in the Treatment of Relapsed/Refractory Lymphoma
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 2 Unknown
NCT03365791 2022-05-27
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
Novartis
Phase 2 Completed
NCT03713320 2022-04-08
SOLAR
miRagen Therapeutics, Inc.
Phase 2 Terminated
NCT00136903 2022-01-31
Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD)
Mesoblast, Ltd.
Phase 2 Completed
NCT00702052 2021-05-25
PILLAR-1
Novartis
Phase 2 Completed
NCT03292406 2021-04-08
CTCL
Galderma R&D
Phase 2 Completed
NCT02605694 2021-03-17
Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO)
SecuraBio
Phase 2 Withdrawn
NCT01327612 2021-02-21
Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)
Amgen
Phase 2 Completed
NCT02927925 2021-01-14
A Study to Assess the Clinical Efficacy and Safety of Daratumumab in Participants With Relapsed or Refractory Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type
Janssen Research & Development, LLC
Phase 2 Completed
NCT03837457 2020-11-19
PRISM
miRagen Therapeutics, Inc.
Phase 2 Terminated
NCT03070964 2020-10-14
A Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma
PharmaMar
Phase 2 Terminated
NCT00451178 2020-07-21
A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only
Eli Lilly and Company
Phase 2 Completed